611 related articles for article (PubMed ID: 10144008)
1. Generics battle brand names over mortality of drug patents.
Betz R
J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
[No Abstract] [Full Text] [Related]
2. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
3. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
4. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
5. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
6. Delaying generic competition--corporate payoffs and the future of Plavix.
Shuchman M
N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
[No Abstract] [Full Text] [Related]
7. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
8. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
9. Biotech industry struggles with generics approval.
Knight J
Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
[No Abstract] [Full Text] [Related]
10. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
Lewis RA
J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
[No Abstract] [Full Text] [Related]
11. Supreme Court to decide whether payments by patent holders to delay production of generics are anticompetitive.
Roehr B
BMJ; 2012 Dec; 345():e8464. PubMed ID: 23236054
[No Abstract] [Full Text] [Related]
12. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
13. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
Panattoni LE
J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
[TBL] [Abstract][Full Text] [Related]
14. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
[TBL] [Abstract][Full Text] [Related]
15. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
16. Using a drug-safety tool to prevent competition.
Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
[No Abstract] [Full Text] [Related]
17. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
Yvon AM
Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
[No Abstract] [Full Text] [Related]
18. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
19. Countering delays in introduction of generic drugs.
Lancet; 2002 Jan; 359(9302):181. PubMed ID: 11812545
[No Abstract] [Full Text] [Related]
20. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
Rea TS
Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
[No Abstract] [Full Text] [Related]
[Next] [New Search]